Karyopharm Therapeutics Inc.
KPTI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 16.1% | 26.4% | -1.7% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 95.2% | 97.2% | 95.7% | 95.6% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -51.2% | -68.3% | -41.2% | -64.2% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -75.2% | -98.2% | -78.2% | -100.8% |
| EPS Diluted | -3.82 | -4.32 | -2.77 | -3.67 |
| % Growth | 11.6% | -56% | 24.5% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |